Use of Endobronchial Ultrasound Scope (EBUS) Transducer to Identify Pneumothorax-A Feasibility Study
Launched by UNIVERSITY OF OKLAHOMA · Sep 14, 2016
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new way to check for a condition called pneumothorax, which is when air leaks into the space between the lung and chest wall and can cause breathing problems. Usually, doctors use a chest X-ray after a procedure called endobronchial ultrasound (EBUS) to see if a pneumothorax has occurred. This study will explore whether using the EBUS tool itself to perform a specialized lung ultrasound can effectively rule out pneumothorax, potentially reducing the need for an X-ray and minimizing radiation exposure for patients.
To participate in this trial, individuals aged 65 to 74 who are undergoing a bronchoscopy may be eligible. This includes patients with a known pneumothorax that requires treatment, and those with severe breathing difficulties on a ventilator. Participants can expect a lung ultrasound to be performed using the EBUS device right after their procedure, which could help doctors quickly determine if there are any issues without needing additional imaging. It's important to note that participants will need to provide informed consent to take part in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
- • 2. Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
- • 3. Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
- Exclusion Criteria:
- • -Absence of informed consent
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials